Am J Epidemiol 2003; 157:784-791.
Copyright © 2003 by Johns
Hopkins Bloomberg School of Public Health
ORIGINAL CONTRIBUTIONS |
Insulin-like Growth Factor I, Insulin-like Growth Factor Binding Protein 3, and Urologic Measures of Benign Prostatic Hyperplasia
1 Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic, Rochester, MN.
2 Department of Health Sciences Research, Division of Biostatistics, Mayo Clinic, Rochester, MN.
3 Merck Research Laboratories, Blue Bell, PA.
4 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
5 Department of Urology, Mayo Clinic, Rochester, MN.
Laboratory studies suggest that insulin-like growth factor I (IGF-I) promotes prostatic growth. The authors evaluated the association between benign prostatic hyperplasia and IGF-I and its binding protein IGFBP-3 in community-dwelling men to determine whether this laboratory finding is manifest at the population level. Participants (n = 471) were Olmsted County, Minnesota, Caucasian males aged 40–79 years in 1990. Urologic measures were assessed from the International Prostate Symptom Score, peak urinary flow rates, prostate volume, and serum prostate-specific antigen (PSA), and serum IGF-I and IGFBP-3 levels were measured. After adjustment for age, the relative odds (odds ratios) of an abnormal urologic measure in men with high versus low serum IGF-I levels were 0.98 (95% confidence interval (CI): 0.66, 1.45) for a symptom score of >7, 1.14 (95% CI: 0.72, 1.80) for a peak urinary flow rate of <12 ml/second, 1.11 (95% CI: 0.72, 1.72) for a prostate volume of >30 ml, and 0.71 (95% CI: 0.46, 1.09) for a PSA level of >1.4 ng/ml. A low IGFBP-3 level was associated with an enlarged prostate (odds ratio = 1.72, 95% CI: 1.05, 2.82), after simultaneous adjustment for IGF-I and age, but not with other urologic measures. These data do not provide evidence for an association between benign prostatic hyperplasia and serum IGF-I.
insulin-like growth factor binding protein 3; insulin-like growth factor I; men; prostate-specific antigen; prostatic hyperplasia; urological manifestations
Abbreviations: Abbreviations: CI, confidence interval; IGF, insulin-like growth factor; IGFBP, insulin-like growth factor binding protein; OR, odds ratio; PSA, prostate-specific antigen; Qmax, peak urinary flow rate.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. L. St. Sauver, A. V. Sarma, D. J. Jacobson, M. E. McGree, M. M. Lieber, C. J. Girman, A. Nehra, and S. J. Jacobsen Associations Between C-Reactive Protein and Benign Prostatic Hyperplasia/Lower Urinary Tract Symptom Outcomes in a Population-based Cohort Am. J. Epidemiol., June 1, 2009; 169(11): 1281 - 1290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Freedland, W. B. Isaacs, E. A. Platz, M. K. Terris, W. J. Aronson, C. L. Amling, J. C. Presti Jr, and C. J. Kane Prostate Size and Risk of High-Grade, Advanced Prostate Cancer and Biochemical Progression After Radical Prostatectomy: A Search Database Study J. Clin. Oncol., October 20, 2005; 23(30): 7546 - 7554. [Abstract] [Full Text] [PDF]
|
|